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Acute tubular necrosis is characterized by activation of the al-
ternative pathway of complement.
Background. Studies in animal models have shown that the
alternative pathway of complement is activated in the kidney
after ischemia/reperfusion. In addition, mice deficient in com-
plement factor B, a necessary component of the alternative
pathway, are protected from ischemic acute renal failure. The
purpose of this study was to determine whether alternative path-
way activation also occurs during the development of ischemic
acute tubular necrosis in the human kidney.
Methods. Biopsies were identified from nine patients with
morphologically normal kidneys and seven patients with evi-
dence of acute tubular necrosis by light microscopy. Immunoflu-
orescence microscopy was used to quantify and localize the
complement activation products C3d and C4d. The results were
correlated with available clinical data.
Results. Similar to mice, small amounts of activated C3d were
present along the tubular basement membrane in normal kid-
neys. However, kidneys from patients with acute tubular necro-
sis had C3d complement deposition along a significantly greater
number of tubules, and many of the tubules were completely
circumscribed. In contrast, C4d was not detectable, indicating
that complement activation occurred primarily via alternative
pathway activation.
Conclusion. Complement activation occurs in human is-
chemic acute tubular necrosis. As in rodents, complement acti-
vation along the tubular basement membrane after ischemia
appears to occur principally via the alternative complement
pathway. Because of this, an inhibitor of the alternative path-
way might limit complement activation and inflammation af-
ter ischemia/reperfusion, thereby protecting the kidney from
ischemic acute renal failure.
Studies in mice have demonstrated that the alterna-
tive complement pathway is activated during renal is-
chemia/reperfusion (I/R), and that mice deficient in this
pathway are protected from ischemic acute renal failure
(ARF). Activation of the classic pathway of complement
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occurs after the I/R of the intestine [1, 2], skeletal muscle
[3, 4], and heart [5]. Rodent studies have shown, however,
that complement activation after I/R of the kidney occurs
almost exclusively via the alternative pathway [6, 7]. Is-
chemic acute tubular necrosis (ATN) is one of the most
common causes of renal failure in humans [8], and alter-
native pathway inhibition may be an effective method of
preventing renal inflammation and injury after I/R.
The pathogenic role of complement activation in
glomerular disease has been deduced from reductions
of plasma levels of complement components during dis-
ease activity, animal models, and glomerular deposits of
complement components as seen by immunofluorescence
[9]. Although the deposition of C3 and C4 in glomerular
diseases is well established, little has been published de-
scribing the pattern of complement deposition in ATN.
We felt that it is important to corroborate the findings
from animal models by examining complement activa-
tion in the human kidney. Although the presence of com-
plement deposits in diseased kidneys does not in and of
itself demonstrate a pathogenic role for complement ac-
tivation, it does provide evidence that complement acti-
vation has occurred and supports the relevance of animal
models that show a similar pattern of deposition. There-
fore, we retrospectively undertook an immunohistologic
analysis of kidney tissue from patients with clinical and
pathologic evidence of ATN.
METHODS
Patient selection
Renal biopsies evaluated at the University of Colorado
Health Sciences Center from 2002 to 2003 were reviewed
with the approval of the Colorado Multiple Institutional
Review Board. Biopsies were fixed in 10% zinc-formalin
and embedded in paraffin by vacuum infiltration. Biop-
sies were then serially sectioned at 4 lm intervals, and
alternate sections were stained with hematoxylin and
eosin, trichrome, periodic acid–Schiff, and silver (Jones’
method). A second biopsy was frozen for immunoflu-
orescence studies. Of those biopsies for which frozen
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Fig. 1. Histologic diagnosis of acute tubular
necrosis. Available biopsies were reviewed,
and those with normal morphology or a patho-
logic diagnosis of ATN were identified. These
images are from patient 8 in Table 1, demon-
strating the changes characteristic of ATN.
The ATN biopsies demonstrated epithelial
sloughing (arrows), epithelial simplification
(arrowhead), loss of brush border, tubular di-
latation, and cast formation. All had acute
rises in the serum creatinine before biopsy,
and all had clinical data consistent with a di-
agnosis of ATN. Electron microscopy of renal
tubules was available for some of the biop-
sies. (A) is stained with trichrome, and (B) is
stained with periodic acid Schiff. (C) The ep-
ithelial cells were characterized by vacuoliza-
tion, apical blebbing (arrowhead), reduced
apical brush border, and basal infoldings (C).
Original magnification was ×200 for (A) and
(B).
Table 1. Patient characteristics
Percentage of
tubules Percentage of
SCr Serum Serum demonstrating tubules
Patient Age Diagnosis mg/dL C3 (82-180) C4 (14-39) Proteinuria C3d (Grade C3d) demonstrating C4d
1 46 Proteinuria, normal
kidney morphology
1.5 “Normal” “Normal” 1.2 g/24 h <10 (2+) N/A
2 49 Proteinuria, normal
kidney morphology
0.8 178 17 1 g/24 h 0 N/A
3 17 Thin GBM disease 0.7 94 N/A 0.5 g/24 h 10 (2+) 0
4 23 Proteinuria, normal
kidney morphology
0.9 156 20 6.2 g/24 h 0 0
5 30 Proteinuria, normal
kidney morphology
0.7 67 33 3.4 g/24 h 10 (2+) 0
6 22 Proteinuria, normal
kidney morphology
0.8 169 N/A 4+ 20 (1+) 0
7 20 Acute tubular necrosis 3.8 N/A N/A 100 mg/dL 15 (3+) N/A
8 80 Acute tubular necrosis 3.9 “Normal” N/A Trace 40 (3+) 0
9 22 Acute tubular necrosis;
10 year history of
MCD, now with focal
segmental
glomerulosclerosis.
1.1 “Normal” N/A 700 mg/24 hr 10 (2+) 0
10 73 Acute tubular necrosis;
moderate
nephrosclerosis
6.7 116 28 4152 mg/24 hr 70 (2+) 0
11 45 Acute tubular necrosis 2.8 N/A N/A 4+ 20 (2+) 0
12 49 Acute tubular necrosis 6.9 102 26 Negative 0 0
13 21 Acute tubular necrosis 2.9 158 47 2474 mg/24 hr 30 (1+) 0
N/A indicates that the data were not available. “Normal” indicates that the referring provider had stated that the value was normal, but the actual value was not available.
tissue was also available, seven biopsies with a patho-
logic diagnosis of ATN were available for further analysis.
Biopsies were classified as having ATN if they demon-
strated epithelial simplification, loss of brush border, api-
cal blebbing, epithelial cell sloughing, tubular dilatation,
and cast formation (Fig. 1). Nine biopsies with no abnor-
malities by light microscopy (minimal change disease or
thin basement membrane disease) were chosen as con-
trols. A biopsy from a patient with type 1 MPGN was
used as a positive control for C3d and C4d staining as
well as C3d and C8 staining.
Clinical data
Charts were reviewed to obtain clinical data for the
patients whose biopsies were chosen for the study. Biop-
sies with histologic evidence of ATN were not included
in the study if the clinical data conflicted with the
diagnosis of ATN. Clinical data were incomplete for
some of the biopsies that had been sent to UCHSC
from other facilities. Available measurements of serum
creatinine, complement levels, and proteinuria are re-
ported for 13 of the 16 biopsies evaluated in this study
(Table 1).
526 Thurman et al: ATN and activation of the complement pathway
Fig. 2. C3 deposition along tubules of nor-
mal kidneys and those with ATN. Low power
views (A) and high power views (B) of
C3d in the tubulointerstitium of morphologi-
cally normal kidneys showed sparse, discrete
patches of C3d deposition. Low (C) and high
(D) power views of C3d deposition in kidneys
with morphologic evidence of ATN demon-
strated regions of heavy C3d deposition in-
volving nearly all of the tubules, and individ-
ual tubules were completely circumscribed by
C3d. (C) and (D) were from the same biopsy
in Figure 1, panels B and D (patient 8 in Table
1). Original magnification was ×100 for (A)
and (C), ×400 for (B) and (D).
Immunofluorescence
Tissue sections were stained with antibodies to C3d
(DakoCytomation, Carpinteria, CA, USA), C4d (Quidel
Corporation, Santa Clara, CA, USA), and C8 (Quidel
Corporation). The antibody to C8 (Quidel product
#A249) binds to the membrane attack complex (MAC).
Four lm sections were air dried and then fixed with ace-
tone for 10 minutes. Nonspecific binding was blocked
with 10% whole goat serum (Cappel, Aurora OH, USA)
in phosphate-buffered saline (PBS). The sections were
incubated overnight at 4◦C with the primary antibodies
diluted 1:150 in PBS. They were washed three times in
PBS, and then incubated with fluorescein isothiocyanate
(FITC) or Rhodamine-conjugated secondary antibod-
ies (Jackson Immunoresearch Laboratories, West Grove,
PA, USA). The slides were imaged with a Nikon T-2000
inverted microscope (Nikon Instruments, Melville, NY,
USA) and slidebook software (Intelligent Imaging Inno-
vations, Denver, CO, USA).
Renal biopsy sections stained for C3d and C4d were
assessed by a renal pathologist in a blinded fashion. The
percentage of tubules with C3d or C4d deposition along
the tubular basement membrane (TBM) was determined.
The intensity of C3d deposition was also graded (0–3+).
Statistical analysis
Data are expressed as mean ± SEM. The unpaired Stu-
dent t test and Mann-Whitney test were used to compare
values between the ATN and non-ATN groups. P values
of less than 0.05 were considered statistically significant.
RESULTS
Human ATN is characterized by C3d deposition along
the tubular basement membrane
Human ATN is characterized by epithelial injury and
tubular dilatation (Fig. 1). Similar to what has been de-
scribed in mice [6], morphologically normal kidneys have
patches of C3d deposition along the TBM of approx-
imately 10% of their tubules (Fig. 2). Kidney sections
with morphologic evidence of ATN, in contrast, had com-
plement deposition on a greater percentage of tubules
(26.4 ± 9.0 vs. 8.3 ± 2.0, P < 0.05 by unpaired Student
t test) (Figs. 2 and 3). When analyzed as nonparamet-
ric data with the Mann-Whitney test, the P value did not
quite reach significance (P = 0.055). Although on average
the kidneys with ATN had more extensive C3d deposi-
tion, the degree of C3d deposition in approximately half
of the kidneys was similar to that seen in morphologically
normal kidneys.
Morphologic injury in ATN is patchy in nature [10].
C3d deposition in kidneys with ATN was also heavy in
some regions, while other regions were relatively spared
(Fig. 2). Injury by light microscopy, as well as C3d de-
position by immunofluorescence, primarily involved the
proximal tubules of affected kidneys. The intensity of
C3d seen along the basement membrane trended toward
being greater in those kidneys with morphologic evidence
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Fig. 3. Kidneys with ATN demonstrated greater complement activation than morphologically normal kidneys. A renal pathologist assessed the
percentage of tubules in each biopsy with C3d deposition (A). Those in kidneys with morphologic evidence of ATN had C3 deposition along a
significantly greater percentage of their tubules than those with normal kidneys by light microscopy. The number next to each data point indicates
which patient in Table 1 it represents. As seen in Figure 2, normal kidneys demonstrated some C3d along the tubular basement membrane. The
intensity of C3d deposition was also graded (B), and those kidneys with morphologic evidence of ATN trended towards a greater intensity of C3d
deposition on affected tubules. The extent of C3d deposition is plotted versus the serum creatinine for patients without ATN (◦) and with ATN ()
(C). For patients with ATN, the available serum creatinine values before the biopsy are plotted (D). The number next to each line indicates which
patient in Table 1 it represents.
of ATN compared to those with normal morphology
(1.9 ± 0.4 vs. 1.0 ± 0.2, P = 0.07 by unpaired Student
t test; when analyzed by the Mann-Whitney test, P =
0.091). The extent of C3d deposition in patients also ap-
peared to correlate with the serum creatinine level (Fig.
3C and Table 1).
Of the biopsies with ATN, several had evidence
of other pathologic processes. The biopsy with the
most extensive deposition of C3d also had evidence of
nephrosclerosis (Table 1). It has been proposed that a
loss of renal mass can cause complement activation within
the remaining kidney by increased ammoniagenesis in the
remnant nephrons [11], and it is possible that this process
contributed to the degree of C3 deposition seen in this
kidney. When the two kidneys with nephrosclerosis or
glomerulosclerosis were excluded from the analysis, the
percentage of tubules with C3d deposition was no longer
significantly different between the ATN and non-ATN
groups (20 ± 7.1 vs. 8.3 ± 2.0, P = 0.07 by unpaired Stu-
dent t test; when analyzed by the Mann-Whitney test, P =
0.19).
Serum C3 and C4 levels were only reported for seven
of the non-ATN kidneys and five of the ATN kidneys
(Table 1). C3 levels were normal in all of the patients
with biopsy-proven ATN for whom this information was
available.
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To determine whether complement activation resulted
in formation of the MAC, sections from four kidneys
were also stained with an antibody to C8 (Fig. 4). MAC
was deposited in a pattern similar to that of C3d. This
demonstrates that complement activation with the tubu-
lointerstitium results in formation of the MAC, as has
been seen in animal studies [12].
Activation of complement in ATN occurs primarily via
the alternative pathway
Dual staining of human kidney sections for C3d and for
C4d demonstrated that basal complement activation, as
well as that which occurred in ATN, was the result of al-
ternative pathway activation. Classic pathway activation,
such as that which occurs in the glomerulus as a result
of immune complex deposition, results in the cleavage of
C4 and C3 generating C4d and C3d, respectively. C4d and
C3d are therefore both generated and colocalize (Fig. 5).
Alternative pathway activation occurs without the gener-
ation of C4d. C3d deposition along the TBM in kidneys
with ATN did not colocalize with C4d (Fig. 5), demon-
strating that cleavage of C3 has primarily occurred by
alternative pathway activation. The low levels of comple-
ment activation in normal kidneys also occurred via the
alternative pathway, as evidenced by the absence of C4d.
DISCUSSION
Studies in animal models have shown abundant depo-
sition of complement activation products in kidneys with
ischemic ATN [12, 13], and there is evidence that comple-
ment inhibition can protect the kidneys from I/R-induced
injury [6, 12–14]. In this study, we demonstrated that mor-
phologically normal human kidneys had intermittent de-
position of C3d along the tubular basement membrane,
indicating that there is a low level of complement acti-
vation at baseline. In kidneys with ATN, however, the
kidneys were characterized by more extensive activation
of complement. Deposition of C3d in these kidneys was
patchy, like the morphologic changes seen by light mi-
croscopy. The kidneys with ATN had more extensive C3d
deposition on average, although deposition in some of the
kidneys with ATN was similar to that of normal kidneys.
It is believed that ammonia, which can react with C3
to form an alternative pathway C3 convertase, activates
complement within the tubulointerstitium of the kidney
[11]. Indeed, the absence of C3 deposition in the kidneys
of mice lacking factor B of the alternative pathway [6]
demonstrates that basal complement activation in mice
appears to occur via the alternative pathway. Given the
absence of C4d in morphologically normal human kid-
neys, basal complement activation in humans may also be
due to alternative pathway activation. The absence of C4d
in the regions of intense C3d deposition within kidneys
with ATN suggests that the increased complement activa-
tion in the tubulointerstitium of these kidneys also results
from alternative pathway activation. In contrast, humoral
rejection of renal allografts is characterized by deposition
of C4d in the peritubular capillaries [15], which reflects
the key role of antibodies and classic pathway activation
in this setting.
Because patients with suspected ATN do not routinely
undergo renal biopsy, the number of biopsies available is
necessarily limited. Furthermore, some of the patients we
identified as having morphologic evidence of ATN also
had other underlying renal abnormalities (Table 1). Un-
fortunately, we could not identify enough potential biop-
sies to restrict our examination to those kidneys without
clinical or histologic evidence of other pathologic pro-
cesses. A study of biopsies rigorously limited to those
without clinical or histologic evidence of any other pro-
cess would be difficult to conduct. Furthermore, given the
heterogeneous patient population with the clinical diag-
nosis of ATN, such strict inclusion criteria for biopsy anal-
ysis would not necessarily be an accurate representation
of patients considered to have ATN.
We have analyzed the data by both parametric and
nonparametric methods because little has been reported
regarding the nature of tubulointerstitial complement de-
position in large populations. While statistically signif-
icant using a Student t test, the percentage of affected
tubules was not statistically significant when evaluated
as nonparametric data using the Mann-Whitney test, al-
though there was still a trend toward greater C3d deposi-
tion in the ATN group (P = 0.055). Furthermore, several
of the kidneys with ATN had C3d deposition that resem-
bled that of normal kidneys. ATN is by nature a patchy
disease, and the biopsies were likely performed at vari-
ous stages in the course of the disease (Fig. 3). A larger
sample size would likely compensate for these variables.
However, when considered together, the greater activa-
tion seen in biopsies with ATN, predominant activation
via the alternative pathway, and the pattern of C3d de-
position along the tubular basement membrane demon-
strate that alternative complement pathway activation in
ATN may parallel that seen in rodents subjected to renal
I/R.
The presence of complement activation products in
kidneys with ATN does not establish a causal role for
complement activation in the pathogenesis of this disease.
Such conclusions can only be extrapolated from animal
studies or verified with a clinical trial of a complement
inhibitor. The similar mechanisms of complement acti-
vation after ischemia, as well as the similar pattern of
C3d deposition along injured tubules, however, do sup-
port the relevance of the animal studies to human disease.
Taken together, therefore, the numerous animal studies
demonstrating a pathogenic role for complement acti-
vation in ATN, as well as the presence of complement
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Fig. 4. Complement activation in kidneys with ATN results in formation of the membrane attack complex. Sections the kidneys were stained for
C3d (red) and C8 (green). A kidney section from the patient with immune complex disease (type I MPGN) was also stained. C8 is evident within
the glomerulus of the kidney with immune complex disease in a pattern similar to that of C3d (colocalization appears yellow). In kidneys with ATN
(patient 10 from Table 1 shown), C8 was also seen along the tubules in a pattern similar to that of the C3d. Original magnification was ×200.
Normal tubules
ATN
Immune complex
disease
C3d C4d Overlay
Fig. 5. Complement activation in kidneys with ATN occurs via the alternative complement pathway. Sections the kidneys were stained for C3d
(red) and C4d (green). A kidney section from a patient with immune complex disease (type I MPGN) was used as a positive control since immune
complexes activate the classic complement pathway and cause deposition of both C3d and C4d. In the control section, C3d and C4d colocalized,
appearing yellow when overlaid. C3d was present abundantly along the tubules of kidneys with ATN (patient 8 from Table 1 shown), and sparsely in
morphologically normal kidneys (patient 6 from Table 1 shown). No C4d was present in any of the kidneys, however, demonstrating that complement
activation in normal kidneys and those with ATN occurs by alternative pathway activation. Original magnification was ×200.
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activation products in human kidneys with ATN, supports
the concept that complement activation contributes to tis-
sue injury in the human disease. Complement inhibitors
have shown promise as therapeutics for cardiac ischemia
[16], and recently for paroxysmal nocturnal hemoglobin-
uria [17]. We have recently developed a novel inhibitory
monoclonal antibody (mAb) to mouse factor B that se-
lectively inhibits the alternative pathway of complement
[18]. This mAb also inhibits in vitro activation of the al-
ternative pathway in human serum and may, therefore,
provide a therapeutic means of inhibiting the alternative
pathway in humans at risk of developing ischemic ARF.
CONCLUSION
We have shown that ATN in humans is characterized
by activation of the alternative pathway of complement.
The pattern of activation is similar to that seen in ani-
mal models, in which abrogation of complement activa-
tion has ameliorated ischemic ARF. Decades of research
have convinced many nephrologists that complement in-
hibition would benefit patients with glomerular disease
[19, 20]. The similarities between human ATN and that
seen in animal models also support serious consideration
of the use of complement inhibitors in patients at risk of
ATN.
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